Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
13
self-reported 11–50 band
Founded
Not recorded
Legal entities
1
ABR
Office countries
2
2 addresses
Funding rounds
2
Post IPO equity · Oct 2025 · US$ 13.2M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
ALTERITY THERAPEUTICS LIMITED
ABN37080699065
Legal entities
Show as table · Alterity Therapeutics: 1 registry entity
| ALTERITY THERAPEUTICS LIMITED | ABN 37080699065 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life.
Our lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA).
Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes.
Alterity has offices in Melbourne, Australia and San Francisco, USA.
Locations
2
Countries with an office address2 addresses on record
AustraliaprimaryUnited States
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | AU |
All codes: AU US
Addresses
- AUMelbourne, VIC 3000Primary
- USNewark, CA 94560
Grid intelligence Members
Funding
Last round · 8 October 2025US$ 13.2MPost IPO equity
Rounds2
Round typePost IPO equity · secondary transaction
Amount (USD)13,200,000
Stage rank6
Investors named0
Since last round3 mo
Funding
Show as table · 2 funding rounds
| Rounds | 2 |
|---|---|
| Axis | 2025 to 2027 |
| Post IPO equity · 8 Oct 2025 | US$ 13.2M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under Alterity Therapeutics?
One Victoria entity on the ABR: ALTERITY THERAPEUTICS LIMITED (ABN 37 080 699 065), high confidence.
How many people work at Alterity Therapeutics?
13 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Alterity Therapeutics have offices?
Two addresses on record across 2 countries. Primary: Melbourne, VIC 3000.
Has Alterity Therapeutics raised funding?
Two rounds. Latest 8 October 2025: post IPO equity, US$13,200,000.
Which companies are listed alongside Alterity Therapeutics?
10 profiles list Alterity Therapeutics as a peer — 85th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Prana Biotechnology lists it back.